NewsBenzingaLongeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome Benzinga 2026.10.26 13:18 (GMT+0) Open on Benzinga Other news Microsoft offers buyouts to around 60,000 employees, reports say What You Need To Know Ahead of Microchip Technology's Earnings Release Stocks Rally Ahead of Busy Week as Crude Oil Prices Ease Ahead of Coca-Cola Earnings, Here's What Barchart Data Says Comes Next for KO Stock A $1 Billion Reason to Buy Skydance Stock Tesla, SpaceX, and a $100 Billion Chip Bet: Elon Musk Is Playing a Different Game
